The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.
Journal
The lancet. Psychiatry
ISSN: 2215-0374
Titre abrégé: Lancet Psychiatry
Pays: England
ID NLM: 101638123
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
22
05
2018
revised:
20
01
2019
accepted:
21
01
2019
pubmed:
25
3
2019
medline:
7
11
2019
entrez:
24
3
2019
Statut:
ppublish
Résumé
Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. We included patients aged 18-64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2-4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5-6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0-16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2-40·0) in London and 50·3% (27·4-66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109). Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health. Medical Research Council, the European Community's Seventh Framework Program grant, São Paulo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, Wellcome Trust.
Sections du résumé
BACKGROUND
BACKGROUND
Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder.
METHODS
METHODS
We included patients aged 18-64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of cannabis use carried the highest odds for psychotic disorder. Using Europe-wide and national data on the expected concentration of Δ
FINDINGS
RESULTS
Between May 1, 2010, and April 1, 2015, we obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites. Daily cannabis use was associated with increased odds of psychotic disorder compared with never users (adjusted odds ratio [OR] 3·2, 95% CI 2·2-4·1), increasing to nearly five-times increased odds for daily use of high-potency types of cannabis (4·8, 2·5-6·3). The PAFs calculated indicated that if high-potency cannabis were no longer available, 12·2% (95% CI 3·0-16·1) of cases of first-episode psychosis could be prevented across the 11 sites, rising to 30·3% (15·2-40·0) in London and 50·3% (27·4-66·0) in Amsterdam. The adjusted incident rates for psychotic disorder were positively correlated with the prevalence in controls across the 11 sites of use of high-potency cannabis (r = 0·7; p=0·0286) and daily use (r = 0·8; p=0·0109).
INTERPRETATION
CONCLUSIONS
Differences in frequency of daily cannabis use and in use of high-potency cannabis contributed to the striking variation in the incidence of psychotic disorder across the 11 studied sites. Given the increasing availability of high-potency cannabis, this has important implications for public health.
FUNDING SOURCE
BACKGROUND
Medical Research Council, the European Community's Seventh Framework Program grant, São Paulo Research Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London and the NIHR BRC at University College London, Wellcome Trust.
Identifiants
pubmed: 30902669
pii: S2215-0366(19)30048-3
doi: 10.1016/S2215-0366(19)30048-3
pmc: PMC7646282
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-436Subventions
Organisme : Medical Research Council
ID : MR/M008436/1
Pays : United Kingdom
Investigateurs
Silvia Amoretti
(S)
Manuel Arrojo
(M)
Grégoire Baudin
(G)
Stephanie Beards
(S)
Miquel Bernardo
(M)
Julio Bobes
(J)
Chiara Bonetto
(C)
Bibiana Cabrera
(B)
Angel Carracedo
(A)
Thomas Charpeaud
(T)
Javier Costas
(J)
Doriana Cristofalo
(D)
Pedro Cuadrado
(P)
Covadonga M Díaz-Caneja
(CM)
Aziz Ferchiou
(A)
Nathalie Franke
(N)
Flora Frijda
(F)
Enrique García Bernardo
(E)
Paz Garcia-Portilla
(P)
Emiliano González
(E)
Kathryn Hubbard
(K)
Stéphane Jamain
(S)
Estela Jiménez-López
(E)
Marion Leboyer
(M)
Gonzalo López Montoya
(G)
Esther Lorente-Rovira
(E)
Camila Marcelino Loureiro
(C)
Giovanna Marrazzo
(G)
Covadonga Martínez
(C)
Mario Matteis
(M)
Elles Messchaart
(E)
Ma Dolores Moltó
(MD)
Juan Nacher
(J)
Ma Soledad Olmeda
(MS)
Mara Parellada
(M)
Javier González Peñas
(J)
Baptiste Pignon
(B)
Marta Rapado
(M)
Jean-Romain Richard
(JR)
José Juan Rodríguez Solano
(JJ)
Laura Roldán Díaz
(L)
Mirella Ruggeri
(M)
Pilar A Sáiz
(PA)
Emilio Sánchez
(E)
Julio Sanjuán
(J)
Crocettarachele Sartorio
(C)
Franck Schürhoff
(F)
Fabio Seminerio
(F)
Rosana Shuhama
(R)
Lucia Sideli
(L)
Simona A Stilo
(SA)
Fabian Termorshuizen
(F)
Sarah Tosato
(S)
Anne-Marie Tronche
(AM)
Daniella van Dam
(D)
Elsje van der Ven
(E)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Br J Psychiatry. 2018 Apr;212(4):227-233
pubmed: 29557758
Lancet Psychiatry. 2015 Mar;2(3):233-8
pubmed: 26359901
Lancet Psychiatry. 2017 Aug;4(8):643-648
pubmed: 28259650
Neuropharmacology. 2017 Sep 15;124:89-104
pubmed: 28634109
Psychol Med. 2019 Jul;49(9):1574-1580
pubmed: 30176957
Addiction. 2015 Dec;110(12):1941-50
pubmed: 26234170
BMC Med. 2004 Apr 28;2:13
pubmed: 15115547
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Soc Psychiatry Psychiatr Epidemiol. 2002 Jul;37(7):329-35
pubmed: 12111025
JAMA Psychiatry. 2016 Mar;73(3):300-1
pubmed: 26864618
Transl Psychiatry. 2016 Nov 29;6(11):e961
pubmed: 27898071
Psychol Med. 2018 Oct;48(14):2346-2352
pubmed: 29382407
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Addiction. 2014 Oct;109(10):1686-94
pubmed: 24894801
Nature. 2015 Sep 24;525(7570):S14
pubmed: 26398733
Addiction. 2017 Mar;112(3):477-485
pubmed: 27743424
JAMA Psychiatry. 2018 Jan 1;75(1):36-46
pubmed: 29214289
Psychol Med. 2006 Oct;36(10):1441-6
pubmed: 16854250
Annu Rev Med. 2016;67:453-66
pubmed: 26515984
Neurosci Biobehav Rev. 2011 Aug;35(8):1779-87
pubmed: 21530584
J Forensic Sci. 2008 Jan;53(1):90-4
pubmed: 18279244
World Psychiatry. 2016 Oct;15(3):195-204
pubmed: 27717258
Drug Test Anal. 2015 Mar;7(3):255-8
pubmed: 25069834
Addiction. 2016 Oct;111(10):1764-73
pubmed: 27082374
Curr Psychiatry Rep. 2016 Feb;18(2):12
pubmed: 26781550
Biol Psychiatry. 2016 Apr 1;79(7):549-56
pubmed: 26386480
Arch Gen Psychiatry. 2005 Sep;62(9):975-83
pubmed: 16143729
Drug Test Anal. 2018 Apr;10(4):628-635
pubmed: 29441730